Your browser doesn't support javascript.
loading
Public T-cell epitopes shared among SARS-CoV-2 variants are presented on prevalent HLA class I alleles
Saskia Meyer; Isaac Blaas; Ravi Chand Bollineni; Marina Delic-Sarac; Trung T Tran; Cathrine Knetter; Ke-Zheng Dai; Torfinn Støve Madssen; John T Vaage; Alice Gustavsen; Weiwen Yang; Lise Sofie Haug Nissen-Meyer; Karolos Douvlataniotis; Maarja Laos; Morten Milek Nielsen; Bernd Thiede; Arne Søraas; Fridtjof Lund-Johansen; Even H Rustad; Johanna Olweus.
Affiliation
  • Saskia Meyer; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univers
  • Isaac Blaas; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univer
  • Ravi Chand Bollineni; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univer
  • Marina Delic-Sarac; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univers
  • Trung T Tran; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway
  • Cathrine Knetter; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univers
  • Ke-Zheng Dai; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway
  • Torfinn Støve Madssen; Department of Circulation and Medical Imaging, Norwegian University of Science and Technology Trondheim (NTNU), Trondheim, Norway
  • John T Vaage; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  • Alice Gustavsen; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway
  • Weiwen Yang; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway ; Institute of Clinical Medicine, Univer
  • Lise Sofie Haug Nissen-Meyer; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway
  • Karolos Douvlataniotis; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univers
  • Maarja Laos; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univers
  • Morten Milek Nielsen; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo; Norway Institute of Clinical Medicine, Universi
  • Bernd Thiede; Department of Biosciences, University of Oslo, Oslo, Norway
  • Arne Søraas; Department of Microbiology, Oslo University Hospital, Oslo, Norway
  • Fridtjof Lund-Johansen; Department of Immunology, University of Oslo, Oslo, Norway; ImmunoLingo Convergence Center, University of Oslo, Oslo, Norway
  • Even H Rustad; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univer
  • Johanna Olweus; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway; Institute of Clinical Medicine, Univers
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-463911
ABSTRACT
T-cell epitopes with broad population coverage may form the basis for a new generation of SARS-CoV-2 vaccines. However, published studies on immunoprevalence are limited by small test cohorts, low frequencies of antigen-specific cells and lack of data correlating eluted HLA ligands with T-cell responsiveness. As the protective role of pre-existing cross-reactivity to homologous peptides is unclear, we aimed to identify SARS-CoV-2-specific minimal epitopes recognized by CD8 T-cells among 48 peptides eluted from prevalent HLA alleles, and an additional 84 predicted binders, in a large cohort of convalescents (n=83) and pre-pandemic control samples (n=19). We identified nine conserved SARS-CoV-2-specific epitopes restricted by four of the most prevalent HLA class I alleles in the Norwegian study cohort, to which responding CD8 T cells were detected in 70-100% of convalescents expressing the relevant HLA allele. Only two of these were derived from the Spike protein, included in current vaccines. We found a strong correlation between immunoprevalence and immunodominance. Thus, the CD8 T-cell response to SARS-CoV-2 is more focused than previously believed. Using a new algorithm, we predict that a vaccine including these epitopes could induce a T-cell response in 83% of Caucasians.
License
cc_by_nc_nd
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Cohort_studies / Observational_studies / Prognostic_studies / Rct Language: En Year: 2021 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Cohort_studies / Observational_studies / Prognostic_studies / Rct Language: En Year: 2021 Document type: Preprint